Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
LifeVantage Co. stock logo
LFVN
LifeVantage
$12.37
+0.2%
$14.94
$5.22
$27.38
$155.26M0.75130,319 shs256,080 shs
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
$2.65
+10.9%
$2.36
$1.61
$11.20
$169.67M0.91708,978 shs3.49 million shs
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
$0.99
+19.0%
$1.07
$0.69
$11.76
$47.37M1.76379,662 shs270,928 shs
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
$1.36
+9.7%
$1.16
$0.54
$1.91
$158.91M0.54448,803 shs297,346 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
LifeVantage Co. stock logo
LFVN
LifeVantage
+0.16%-2.68%-15.16%-44.78%+102.79%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
+10.88%+17.26%+23.26%-33.25%-61.54%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
+19.03%+16.18%+4.09%-20.88%-90.56%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
+9.68%+3.82%+25.93%+97.10%+110.01%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
LifeVantage Co. stock logo
LFVN
LifeVantage
3.9902 of 5 stars
3.51.01.72.72.92.50.6
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
2.033 of 5 stars
3.61.00.00.03.81.70.0
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
2.5513 of 5 stars
3.42.00.00.02.71.71.3
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.5129 of 5 stars
0.03.00.00.02.01.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
LifeVantage Co. stock logo
LFVN
LifeVantage
3.00
Buy$30.50146.56% Upside
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3.10
Buy$19.63640.57% Upside
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
2.71
Moderate Buy$7.50658.34% Upside
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest STTK, TLSA, LFVN, and LRMR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/27/2025
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
3/27/2025
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/25/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
3/25/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$26.00 ➝ $26.00
3/25/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $16.00
3/25/2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$13.00 ➝ $10.00
3/17/2025
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/17/2025
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$4.00
(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
LifeVantage Co. stock logo
LFVN
LifeVantage
$212.15M0.73$0.65 per share19.03$2.38 per share5.20
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/A$1.86 per shareN/A
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
$5.72M8.28N/AN/A$3.41 per share0.29
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/A$0.05 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.94M$0.5622.09N/A3.46%34.29%15.04%5/6/2025 (Estimated)
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$36.95M-$1.30N/AN/AN/AN/A-35.87%-32.37%5/8/2025 (Estimated)
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-$87.30M-$1.49N/AN/AN/A-1,156.46%-61.92%-54.49%5/1/2025 (Estimated)
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
-$17.69MN/A0.00N/AN/AN/AN/AN/A

Latest STTK, TLSA, LFVN, and LRMR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.42N/AN/AN/AN/AN/A
5/6/2025Q3 2025
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.1633N/AN/AN/A$60.99 millionN/A
5/1/2025Q4 2024
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-$0.29N/AN/AN/AN/AN/A
4/30/2025Q1 2025
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.42-$0.46-$0.04-$0.46N/AN/A
3/27/2025Q4 2024
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-$0.38-$0.37+$0.01-$0.37$1.00 millionN/A
3/24/2025Q4 2024
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
-$0.29-$0.45-$0.16-$0.45N/AN/A
2/5/2025Q2 2025
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.14$0.22+$0.08$0.19$67.41 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.161.29%N/A28.57%N/A
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/AN/AN/AN/AN/A
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
N/AN/AN/AN/AN/A
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/AN/A

Latest STTK, TLSA, LFVN, and LRMR Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/3/2025
LifeVantage Co. stock logo
LFVN
LifeVantage
quarterly$0.040.7%3/3/20253/3/20253/17/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.66
1.03
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
N/A
13.10
13.10
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
N/A
7.96
7.96
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/A
0.85
N/A

Institutional Ownership

CompanyInstitutional Ownership
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
91.92%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
58.74%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/A

Insider Ownership

CompanyInsider Ownership
LifeVantage Co. stock logo
LFVN
LifeVantage
20.65%
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
4.50%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
10.50%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
39.82%
CompanyEmployeesShares OutstandingFree FloatOptionable
LifeVantage Co. stock logo
LFVN
LifeVantage
26012.55 million9.96 millionOptionable
Larimar Therapeutics, Inc. stock logo
LRMR
Larimar Therapeutics
3064.03 million61.57 millionOptionable
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
10047.90 million42.73 millionOptionable
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
8116.85 million63.43 millionOptionable

Recent News About These Companies

Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025
Tiziana submits FDA investigational new drug application
Tiziana Life Sciences expects to complete Long Covid study in Q2

New MarketBeat Followers Over Time

Media Sentiment Over Time

LifeVantage stock logo

LifeVantage NASDAQ:LFVN

$12.37 +0.02 (+0.16%)
As of 04/30/2025 04:00 PM Eastern

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Larimar Therapeutics stock logo

Larimar Therapeutics NASDAQ:LRMR

$2.65 +0.26 (+10.88%)
As of 04/30/2025 04:00 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Shattuck Labs stock logo

Shattuck Labs NASDAQ:STTK

$0.99 +0.16 (+19.03%)
As of 04/30/2025 04:00 PM Eastern

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Tiziana Life Sciences stock logo

Tiziana Life Sciences NASDAQ:TLSA

$1.36 +0.12 (+9.68%)
As of 04/30/2025 04:00 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.